| Clinical data | |
|---|---|
| Trade names | Altuviiio |
| Other names | BIVV001; antihemophilic factor (recombinant), Fc-VWF-XTEN fusion protein-ehtl |
| License data | |
| Routes of administration | Intravenous |
| ATC code |
|
| Legal status | |
| Legal status | |
| Identifiers | |
| CAS Number | |
| DrugBank | |
| UNII | |
| KEGG | |
| Chemical and physical data | |
| Formula | C13690H20958N3682O4376S136 |
| Molar mass | 311501.81 g·mol−1 |
Efanesoctocog alfa, sold under the brand name Altuviiio, is a medication used for the treatment of hemophilia A (congenital factor VIII deficiency).[1][2]
Efanesoctocog alfa was approved for medical use in the United States in February 2023.[1][2][3][4]
Medical uses
Efanesoctocog alfa is a recombinant DNA-derived, Factor VIII concentrate indicated for use in adults and children with hemophilia A (congenital factor VIII deficiency) for routine prophylaxis to reduce the frequency of bleeding episodes; on-demand treatment & control of bleeding episodes; and perioperative management of bleeding.[1][2]
References
- 1 2 3 4 "Altuviiio (antihemophilic factor- recombinant, fc-vwf-xten fusion protein-ehtl kit". DailyMed. 31 March 2023. Retrieved 7 May 2023.
- 1 2 3 "Altuviiio". U.S. Food and Drug Administration. 21 March 2023. Retrieved 7 May 2023.
This article incorporates text from this source, which is in the public domain. - ↑ AB, Swedish Orphan Biovitrum (24 February 2023). "FDA approves once-weekly efanesoctocog alfa, a new class of high-sustained factor VIII therapy for haemophilia A: Swedish Orphan Biovitrum AB" (Press release). Swedish Orphan Biovitrum AB. Retrieved 7 May 2023 – via PR Newswire.
- ↑ "Press Release: FDA approves once-weekly Altuviiio, a new class of factor VIII therapy for hemophilia A that offers significant bleed protection" (Press release). Sanofi. 23 February 2023. Retrieved 7 May 2023.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.